Abstract
Antibody drug conjugates (ADCs) for oncology applications are chemotherapeutic agents designed to selectively deliver cytotoxic drug payloads to neoplastic tissue. This book chapter reviews the latest approaches for high drug loaded ADCs. The primary focus of this review is related to ADC drug payload and antibody-drug bioconjugation linker selection strategies resulting in biotherapeutics with improved physicochemical properties, efficacy, and pharmacokinetics. A separate section of this chapter gives a brief overview of antibody targeted nanotherapeutics, a growing and diverse class of anti-cancer agents specifically designed for delivery of significant amounts of drug payload. New strategies to design the highly potent antibody targeted agents discussed in this chapter provide the opportunity to expand the list of drug payloads suitable for ADC applications and introduce agents with new mechanisms of action, which in turn may potentially lead to improvement in therapeutic index of the ADCs for the treatment of cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ADC:
-
Antibody drug conjugate
- ADCM:
-
Antibody/drug-conjugated micelle
- AM:
-
Aminomethylene
- DAR:
-
Drug antibody ratio
- EPR:
-
Enhanced permeability and retention
- F-HPA:
-
F-hydroxypropylamide
- GGFG:
-
Glycine-glycine-phenylalanine-glycine
- HPMA:
-
N-(2-hydroxypropyl) methacrylamide
- IFN:
-
Interferon
- IL:
-
Immunoliposome
- MAP-CPT:
-
Mucic acid polymer conjugate of camptothecin
- mDPR:
-
Maleimidodiaminopropionic acid
- MDR:
-
Multidrug resistance
- MMAD:
-
Monomethyl auristatin D
- MMAE:
-
Monomethyl auristatin E
- MMAF:
-
Monomethyl auristatin F
- OC:
-
Ovarian cancer
- PBD:
-
pyrrolobenzodiazepine
- P-gp:
-
P-glycoprotein
- PHF:
-
Poly-1-hydroxymethylethylene hydroxymethylformal
- PK:
-
Pharmacokinetics
- RES:
-
Reticular endothelial system
- SCID:
-
Severe combined immunodeficiency disease
- TCEP:
-
Tris-carboxyethylphosphine
- TI:
-
Therapeutic index
- TNBC:
-
Triple-negative breast cancer
- TOPO I:
-
Topoisomerase I
- val-cit-PABC:
-
Valine-citrulline-p-aminobenzylcarbamate
References
A pilot study of 64-Cu labeled brain PET/MRI for MM-302, a novel HER2 targeting agent, in advanced HER2+ cancer with brain metastases – NCT02735798
A study evaluating MM-310 in patients with solid tumors – NCT03076372
Ali MF, Salah M, Rafea M, Saleh N (2008) Liposomal methotrexate hydrogel for treatment of localized psoriasis: preparation, characterization and laser targeting. Med Sci Monit 14(12):PI66–PI74
Anami Y, Xiong W, Gui X, Deng M, Zhang CC, Zhang N, An Z, Tsuchikama K (2017) Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drugconjugates with high potency. Org Biomol Chem 15(26):5635–5642
Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O’Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT (2017) Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast Cancer. J Clin Oncol 35:2141
Bauer TM, Spigel D, Ready N, Morgensztern D, Glisson BS, Byers LA, Burris H, Robert F, Strickland DK, Pietanza MC, Govindan R, Dylla SJ, Peng S, Rudin C (2016) ORAL02.01: safety and efficacy of single-agent Rovalpituzumab Tesirine, a DLL3-targeted ADC, in recurrent or refractory SCLC. Topic Med Oncol J Thorac Oncol 11S(11):S252–S253
Bergstrom DA A, Bodyak N, Park PU, Yurkovetskiy A, DeVit M, Yin M, Poling L, Thomas JD, Gumerov D, Xiao D, Ter-Ovanesyan E, Qin L, Uttard A, Johnson A, Lowinger TB (2015) XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer. 38th annual SABCS Dec. 8–12, 2015, Publication Number: P4-14-28
Bergstrom DA, Bodyak N, Yurkovetskiy A, Park PU, DeVit M, Yin M, Poling L, Thomas JD, Gumerov D, Xiao D, Ter-Ovanesyan E, Qin L, Uttard U, Johnson A, Lowinger TB (2015) A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 75(15 Suppl):Abstract nr LB-231
Bergstrom D, Bodyak N, Yurkovetskiy A, Poling L, Yin M, Protopopova M, Devit M, Qin L, Gumerov D, Ter-Ovanesyan E, Mosher R, Lowinger T (2016) A NaPi2b antibody-drug conjugate induces durable complete tumor regressions in patient-derived xenograft models of NSCLC. IASLC 17th World Conference on Lung Cancer; Dec 4-7, Vienna, Austria. Abstract nr 5769
Bodyak N, Yurkovetskiy A, Yin M, Gumerov G, Bollu R, Conlon P, Gurijala VR, McGillicuddy D, Stevenson C, Ter-Ovanesyan E, Park PU, Poling P, Lee W, DeVit M, Xiao D, Qin L, Lowinger TB, Bergstrom DA (2016) Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models. In: Proceedings of the 107th annual meeting of the American Association for Cancer Research; 2016; New Orleans, LA: AACR. Cancer Res 76(14 Suppl):Abstract nr 1194
Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7(6):1490–6. Erratum in: Clin Cancer Res 2002;8(1):300
Bulbake U, Doppalapudi S, Kommineni N, Khan W (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics 9(2):1–33
Burke PJ, Hamilton JZ, Jeffrey SC, Hunter JH, Doronina SO, Okeley NM, Miyamoto JB, Anderson ME, Stone IJ, Ulrich ML, Simmons JK, McKinney EE, Senter PD, Lyon RP (2017) Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates. Mol Cancer Ther 16(1):116–123
Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM (2011) Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 17(10):3157–3169
Crosasso P, Brusa P, Dosio F, Arpicco S, Pacchioni D, Schuber F, Cattel L (1997) Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J Pharm Sci 86(7):832–839
de Goeij BE, Lambert JM (2016) New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 40:14–23
Elias DJ, Hirschowitz L, Kline LE, Kroener JF, Dillman RO, Walker LE, Robb JA, Timms RM (1990) Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res 50(13):4154–4159
Eloy JO, Petrilli R, Chesca DL, Saggioro FP, Lee RJ, Marchetti JM (2017) Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. Eur J Pharm Biopharm 115:159
Eloy JO, Petrilli R, Brueggemeier RW, Marchetti JM, Lee RJ (2017) Rapamycin-loaded immunoliposomes functionalized with trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells. Anti Cancer Agents Med Chem 17(1):48–56
Etrych T, Mrkvan T, Ríhová B, Ulbrich K (2007) Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy. J Control Release 122(1):31–38
Etrych T, Strohalm J, Kovár L, Kabesová M, Ríhová B, Ulbrich K (2009) HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity. J Control Release 140(1):18–26
Gaddy DF, Lee H, Zheng J, Jaffray DA, Wickham TJ, Hendriks BS (2015) Whole-body organ-level and kidney microdosimetric evaluations of 64Cu-loaded HER2/ErbB2- targeted liposomal doxorubicin (64Cu-MM-302) in rodents and primates. EJNMMI Res 5:24
Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, Rennard R, Xu L, Schoerberl B, Marks JD, Drummond DC, Lugovskoy AA (2017) Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs 9(1):58–67. Epub 2016 Nov 17
Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM (2015) Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget 6(26):22496–22512
Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM (2013) Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 12(6):968–978
Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, Sharkey RM, Goldenberg DM (2015) Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm 12(6):1836–1847
Gray J, Cubitt CL, Zhang S, Chiappori A (2012) Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther 13(8):614–622
Gupta N, Kancharla J, Kaushik S, Ansari A, Hossain S, Goyal R, Pandey M, Sivaccumar J, Hussain S, Sarkar A, Sengupta A, Mandal SK, Roy M, Sengupta S (2017) Development of a facile antibody–drug conjugate platform for increased stability and homogeneity. Chem Sci 8:2387
Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063–7070
Han H, Davis ME (2013) Single-antibody, targeted nanoparticle delivery of camptothecin. Mol Pharm 10(7):2558–2567
Han H, Davis ME (2013) Targeted nanoparticles assembled via complexation of boronic-acid-containing targeting moieties to diol-containing polymers. Bioconjug Chem 24(4):669–677
Harada M, Tsuchiya M, Miyazaki R, Inoue T, Tanaka R, Yanagisawa Y, Ito M, Yu I, Naito K (2016) Preclinical evaluation of NC-6201, an antibody/drug-conjugated micelle incorporating novel hemiasterlin analogue E7974. AACR 107th annual meeting 2016; April 16–20, 2016; New Orleans. Abstract 1368
Hoch U, Staschen CM, Johnson RK, Eldon MA (2014) Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol 74(6):1125–1137
Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038–1044
Jain NK, Tare MS, Mishra V, Tripathi PK (2015) The development, characterization and in vivo anti-ovarian cancer activity of poly(propylene imine) (PPI)-antibody conjugates containing encapsulated paclitaxel. Nanomedicine 11(1):207–218
Jevsevar S, Kunstelj M, Porekar VG (2010) PEGylation of therapeutic proteins. Biotechnol J 5(1):113–128
Jiang P, Mukthavaram R, Chao Y, Bharati IS, Fogal V, Pastorino S, Cong X, Nomura N, Gallagher M, Abbasi T, Vali S, Pingle SC, Makale M, Kesari S (2014) Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. J Transl Med 12:13
Kato Y, Harada M, Saito H, Hayashi T. Active targeting polymer micelle encapsulating drug, and pharmaceutical composition. US Patent Application 20100221320
Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66(13):6732–6740
Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Building DDC (2012) Characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol 502:139–166
Kulhari H, Pooja D, Shrivastava S, Kuncha M, Naidu VG, Bansal V, Sistla R, Adams DJ (2016) Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer. Sci Rep 6:23179
Kullberg M, Mann K, Anchordoquy TJ (2012) Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO. Mol Pharm 9(7):2000–2008
Lambert JM, Chari RVJ (2014) Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 57:6949–6964
Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS (2017) 64Cu-MM-302 positron emission tomography quantifies variability of enhanced permeability and retention of nanoparticles in relation to treatment response in patients with metastatic breast cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-16-3193
Levengood MR, Zhang X, Emmerton KK, Hunter JH, Peter D Senter PD (2017) Development of homogeneous dual-drug ADCs: application to the co-delivery of auristatin payloads with complementary antitumor activities. Proceedings of the American Association for Cancer Research, vol 58. April 2017, Abstract# 982, p 250
Levengood MR, Zhang X, Hunter JH, Emmerton KK, Miyamoto JB, Lewis TS, Senter PD (2017) Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates. Angew Chem Int Ed Engl 56(3):733–737
Lin K, Rubinfeld B, Zhang C, Firestein R, Harstad E, Roth L, Tsai SP, Schutten M, Xu K, Hristopoulos M, Polakis P (2015) Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers. Clin Cancer Res 21(22):5139–5150
LoRusso P, Krop I, Miller K et al (2015) A Phase 1 study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer (mBC). Presented at: 2015 AACR Annual Meeting; April 18–22, 2015; Philadelphia. Abstract CT234
Lyon RP, Bovee TD, Doronina SO, Burke PJ, Hunter JH, Neff-LaFord HD, Jonas M, Anderson ME, Setter JR, Senter PD (2015) Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 33(7):733–735
Ma P, Zhang X, Ni L, Li J, Zhang F, Wang Z, Lian S, Sun K (2015) Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab. Int J Nanomedicine 10:2173–2190
Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, Kirpotin DB, Park JW (2005) Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 65(24):11631–11638
Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R, Rochlitz C (2012) Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol 3(12):1234–1241
Mantaj J, Jackson PJ, Rahman KM, Thurston DE (2017) From Anthramycin to Pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs). Angew Chem Int Ed Engl 56(2):462–488
Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, Wilhelm A, Modafferi HA, Singh R, Pinkas J, Goldmacher V, Lambert JM, Chari RV (2016) A new class of antibody-drug conjugates with potent DNA alkylating activity. Mol Cancer Ther 15(8):1870–1878
MM-302 plus trastuzumab vs. chemotherapy of physician’s choice plus trastuzumab in HER2-positive locally advanced/metastatic breast cancer patients (HERMIONE) – NCT02213744
Nakada T, Masuda T, Naito H, Yoshida M, Ashida S, Morita K, Miyazaki H, Kasuya Y, Ogitani Y, Yamaguchi J, Abe Y, Honda T (2016) Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads. Bioorg Med Chem Lett 26(6):1542–1545
Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC (2004) Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 8(4):335–353
Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T (2016) DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 22(20):5097–5108
Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T (2016) Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 107(7):1039–1046
Omelyanenko V, Kopecková P, Gentry C, Shiah JG, Kopecek J (1996) HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J Drug Target 3(5):357–373
Pabst M, McDowell W, Manin A, Kyle A, Camper N, De Juan E, Parekh V, Rudge F, Makwana H, Kantner T, Parekh H, Michelet A, Sheng X, Popa G, Tucker C, Khayrzad F, Pollard D, Kozakowska K, Resende R, Jenkins A, Simoes F, Morris D, Williams P, Badescu G, Baker MP, Bird M, Frigerio M, Godwin A (2017) 18. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates. J Control Release 253:160–164
Pagnan G, Stuart DD, Pastorino F, Raffaghello L, Montaldo PG, Allen TM, Calabretta B, Ponzoni M (2000) Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD2-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst 92(3):253–261
Palmerston Mendes L, Pan J, Torchilin VP (2017) Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules 22(9):1401
Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, Benz CC (1997) Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 118(2):153–160
Pérez-Herrero E, Fernández-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79
Phase I/II study of U3-1402 in subjects with human epidermal growth factor receptor 3 (HER3) positive metastatic breast cancer – NCT02980341
Řihová B, Kopeček J (1985) Biological properties of targetable poly[N-(2-hydroxypropyl)-methacrylamide]-antibody conjugates. J Control Release 2:289–310
Sapra P, Allen TM (2002) Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62(24):7190–7194
Schneck D, Butler F, Dugan W, Littrell D, Petersen B, Bowsher R, DeLong A, Dorrbecker S (1990) Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas. Clin Pharmacol Ther 47(1):36–41
Senter PD, Sievers EL (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nature Biotech 30:631–637
Simmons J, Zapata F, Neff-Laford H, Hunter J, Cochran J, Burke P, Lyon RP. Reducing toxicity of antibody-drug conjugates through modulation of pharmacokinetics. Proceedings of the American Association for Cancer Research. Vol 58. April 2017, Abstract# 60. p 15
Stathopoulos GP, Antoniou D, Dimitroulis J, Stathopoulos J, Marosis K, Michalopoulou P (2011) Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer. Cancer Chemother Pharmacol 68(4):945–950
Stein EM, Stein A, Walter RB et al (2014) Interim analysis of a phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML) [abstract]. Blood 124(21). Abstract 623
Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, Casas MG, Dorywalska M, Farias S, Pios A, Lui V, Dushin R, Zhou D, Navaratnam T, Tran TT, Sutton J, Lindquist KC, Han B, Liu SH, Shelton DL, Pons J, Rajpal A (2015) Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol 33(7):694–696
Sun X, Ponte JF, Yoder NC, Laleau R, Coccia J, Lanieri L, Qiu Q, Wu R, Hong E, Bogalhas M, Wang L, Dong L, Setiady Y, Maloney EK, Ab O, Zhang X, Pinkas J, Keating TA, Chari R, Erickson HK, Lambert JM (2017) Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug Chem 28(5):1371–1381
Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17(2):478–484
Ueno S, Hirotani K, Abraham R, Blum S, Frankenberger B, Redondo-Muller M, Bange J, Ogitani Y, Zembutsu A, Morita K, Nakada T, Majima S, Abe Y, Agatsuma T (2017) U3-1402a, a novel HER3-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent antitumor effıcacy. In: Proceedings of the 108th Annual Meeting of the American Association for Cancer Research; 2017; Washington, DC: AACR; Cancer Res 76(14 Suppl):Abstract nr 3092
Ulbrich K, Etrych T, Chytil P, Jelínková M, Ríhová B (2004) Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J Drug Target 12(8):477–489
Yang H (2016) Targeted nanosystems: advances in targeted dendrimers for cancer therapy. Nanomedicine 12(2):309–316
Yurkovetskiy AV, Fram RJ (2009) XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv Drug Deliv Rev 61(13):1193–1202
Yurkovetskiy A, Choi S, Hiller A, Yin M, McCusker C, Syed S, Fischman AJ, Papisov MI (2005) Fully degradable hydrophilic polyals for protein modification. Biomacromolecules 6(5):2648–2658
Yurkovetskiy A, Bodyak N, Yin M, Thomas J, Conlon P, Stevenson C, Uttard U, Qin L, Gumerov D, Ter-Ovaneysan E, DeVit M, Lowinger TB (2013) Advantages of polyacetal polymer-based antibody drug conjugates employing cysteine bioconjugation. In: Proceedings of the 104th annual meeting of the American Association for Cancer Research; 2013; Washington, DC: AACR; Cancer Res 73(8 Suppl):Abstract nr 4331
Yurkovetskiy A, Bodyak N, Yin M, Thomas JD, Conlon PR, Stevenson CA, Uttard A, Qin LL, Gumerov DR, Ter-Ovanesyan E, Gurijala VR, McGillicuddy D, Glynn RE, DeVit M, Poling LL, Park PU, Lowinger TB (2014) Antibody drug conjugate (ADC) designed with Fleximer® platform enables high drug-loading of payloads and potent anti-tumor activities in tumor cells with low target expression. The Antibody Biology & Engineering Gordon Research Conference. Lucca (Barga), March 23–28
Yurkovetskiy AV, Yin M, Bodyak N, Stevenson CA, Thomas JD, Hammond CE, Qin L, Zhu B, Gumerov DR, Ter-Ovanesyan E, Uttard A, Lowinger TB (2015) A polymer-based antibody-vinca drug conjugate platform: characterization and preclinical efficacy. Cancer Res 75(16):3365–3372
Yurkovetskiy A, Gumerov D, Ter-Ovanesyan E, Conlon P, Devit M, Bu C, Bodyak N, Lowinger T, Bergstrom D (2017) Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate. In: Proceedings of the 108th annual meeting of the American Association for Cancer Research; 2017; Washington, DC: AACR; Cancer Res 76(14 Suppl):Abstract nr 48
Zhang L, Fang Y, Kopeček J, Yang J (2017) A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin’s lymphomas. Eur J Pharm Sci. Accepted manuscript 103:36–46
Acknowledgements
The authors thank Radha Iyengar for thoughtful and insightful comments on the manuscript. The authors also thank Theresa E. Singleton, PhD of Singleton Science, LLC for editorial support, which was funded by Mersana Therapeutics in accordance with Good Publication Practice (GPP3) guidelines.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Bodyak, N., Yurkovetskiy, A.V. (2018). Delivering More Payload (High DAR ADCs). In: Damelin, M. (eds) Innovations for Next-Generation Antibody-Drug Conjugates. Cancer Drug Discovery and Development. Humana Press, Cham. https://doi.org/10.1007/978-3-319-78154-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-78154-9_9
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-78153-2
Online ISBN: 978-3-319-78154-9
eBook Packages: MedicineMedicine (R0)